No annual revenue total was found in ENLIVEN THERAPEUTICS, INC.'s SEC filings.
Enliven Therapeutics, Inc. (ELVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$70.5 million. As of Sep 30, 2026 it held $884.4 million in cash and investments and $1.3 million in total debt.
Revenue
—
Net income (TTM)
$-113.48M
-16.7% vs year-ago TTM
Operating cash flow (TTM)
$-66.22M
+7.6% vs year-ago TTM
Free cash flow (TTM)
$-66.41M
+7.5% vs year-ago TTM
EPS (TTM)
$-1.69
+7.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
59.80M
+22.0% vs prior year
Net cash
$883.04M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1672619
- Former names
- IMARA Inc. (until Feb 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$51.4M |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M | -$51.4M |
| Diluted EPS | -$1.83 | -$1.89 | -$2.01 | -$12.05 | — |
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$46.8M |
| Free cash flow | -$70.5M | -$73.2M | -$61.4M | -$32.7M | -$46.8M |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M |
| Stockholders' equity | $459.6M | $309.8M | $245.9M | -$76.8M | -$42.9M |
| Cash and investments | $462.6M | $313.4M | $253.1M | $75.5M | $90.3M |
| Total debt | $399,000 | — | $335,000 | — | $652,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 12, 2026 | Jun 11, 2026 |
All 798 Enliven Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.